Cameron Szakacs

Dr. Szakacs serves as Milestone’s VP of Drug Development and has been with the company since 2017. He has over 25 years of drug development and clinical research experience in the pharmaceutical industry across start-up, mid-size and large pharma companies.

Prior to joining Milestone, Cameron was with United Therapeutics where he held product development responsibilities for one of the company’s key portfolio products for pulmonary arterial hypertension. He previously served as a senior director of drug development at Lundbeck North America following its acquisition of Chelsea Therapeutics International, where he managed Chelsea’s drug development efforts and served as a senior member of the interdepartmental team that filed a successful NDA, secured favorable recommendations from two FDA Advisory Committee meetings and achieved U.S. marketing approval for Northera, an orphan drug for the treatment of symptomatic neurogenic orthostatic hypotension. Dr. Szakacs has also had roles in increasing responsibilities in drug development with Cellectar Biosciences, Nektar Therapeutics and Hoffmann-La Roche (Canada).

Dr. Szakacs taught and conducted research at the University of Saskatchewan, where he received his Ph.D. in Pharmacology.